Ulm is the tenth, and youngest, site of the DZNE: Since 2018, scientists at the DZNE Ulm have been focusing in particular on rarer, but very serious nerve diseases, such as amyotrophic lateral sclerosis (ALS), types of frontotemporal lobar degeneration (FTLD), and Huntington’s disease. The goal of the site in Ulm is to translate the scientific results from fundamental research into clinical applications as quickly as possible: Plans call for developing new diagnostic and therapeutic procedures so that patients can benefit from them. New formats for clinical studies are being created as well. To this end, a clinical study center is currently being established at the DZNE Ulm, in close cooperation with the Department of Neurology at the Ulm University Hospital.
The DZNE experts in Ulm are particularly interested in biomarkers, which are measurable biological indicators that can be used to detect a disease and assess how it will progress. To achieve this, the site is developing new technologies that can be used to detect biomarkers. Research in Ulm also focuses on therapeutic concepts that target pathogenic genetic defects.
DZNE cooperation partner
Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE)
Oberer Eselsberg 45
Mechanisms of Propagation
Prof. Dr. Karin Danzer
Translational Protein Biochemistry
Prof. Dr. Tobias M. Böckers
Translational Mass Spectrometry and Biomarker Research
Priv.-Doz. Dr. Patrick Öckl
Metabolic Changes in Neurodegeneration
apl. Prof. Dr. Dr. Francesco Roselli